Danish Dementia Research Centre, Department of Neurology, Rigshospitalet.
Copenhagen, Copenhagen Ø, 2100, Denmark
NCT Number: NCT01681602
Background: Current treatment for Alzheimer's disease (AD) is symptomatic and can only temporarily slow down progression.
Exercise has the potential to improve cognition, psychological symptoms, physical performance and quality of life, but evidence is scarce. Previous trials are short, often underpowered and involving home based light exercise programs. Most have included nursing homes residents with severe or undefined dementia. The aim of the ADEX trial is to establish whether exercise is effective in improving cognition, physical performance and quality of life as well as reducing the prevalence of psychological symptoms among AD patients.
Methods: The ADEX Trial is a multicentre, single-blind, randomized clinical trial. Based on power calculations the investigators plan to recruit 192 home-dwelling patients aged 50-90 years with mild to moderate AD. The participants will be randomly allocated into two groups: An intervention group attending 16 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week and a control group only receiving usual care. The hypothesis is that aerobic exercise will improve physical function, the cognitive and daily functioning and quality of life in people with mild to moderate AS.
Blood sampling will be performed in all subjects to examine effects on biomarkers. A subgroup of the patients will also undergo MRI, PiB-PET and lumbar puncture to investigate structural changes and β-amyloid accumulation.
Further, a health-economic analysis will be performed.
Recruitment was started in January 2012. Last study visits are planned to be performed in January 2014 and results will be available in 2014. This RCT will contribute to evidence regarding the potential effects of a systematic program of physical exercise for patients with Alzheimer's disease.
Looking for future studies?
Notify Me50 year–90 year
All sexes
Interventional
Phase 3
Copenhagen, Copenhagen Ø, 2100, Denmark
see protocol article
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
Other names: Endurance training
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Timed up and go test (TUG), 10 m walk, 10m Dual-Task, 400m fast walking, Sit-to-stand (number in 30 sec.)(STS).
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Time frame: Change in score from baseline to 16 weeks
Rigshospitalet, Denmark
Other
Preserving Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise
Acronym: ADEX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03876314
Alzheimer Disease, Behavior
Greensboro, North Carolina, United States
View Trial DetailsNCT03670615
Alzheimer Disease, Behavior
Toronto, Ontario, Canada
View Trial DetailsNCT03896711
Alzheimer Disease, Behavior
Baltimore, Maryland, United States
View Trial DetailsNCT02444078
Alzheimer Disease, Behavior
Bruay-sur-l'Escaut, France
View Trial Details